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Background/Aims
Gastroesophageal reflux disease is a highly prevalent disease. Assessing treatment efficacy is critical in that clinical endpoints 
are properly evaluated. Clinical tools for symptoms severity assessment should be discriminative, predictive and evaluative.
Methods
In this study we compared a patient-oriented symptoms evaluation (ReQuest
TM) vs a structured interview assessment initiated 
by a physician (sickness impact profile [SIP]). Both questionnaires were analyzed in a multidimensional space using latent 
factors. Five dimensions were found: 1 for the short ReQuest
TM questionnaire and 4 for SIP.
Results
We included 1,522 women and 1,296 men; mean age was 36 ± 7 years, and mean body mass index was 26 ± 4. The score 
questionnaire assessment evaluation by physicians and patients did not correlate between them (between r = 0.03 and 0.26) 
except nausea and sleep disorder (r = 0.45 and 0.51) but both were sensitive enough to detect changes after treatment (P 
＜  0.05). Medical specialty of the physician showed effect on the score of both, ReQuest
TM and SIP evaluation. Questionnaire 
variance decomposition due to specialist was only 2% (P ＜  0.05).
Conclusions
While both evaluations are orthogonal (non-correlated), meaning patients and physicians measured diverse aspects of the same 
disease, they both were able to measure patient’s improvement with treatment.
(J Neurogastroenterol Motil 2011;17:381-386)
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Introduction
Gastroesophageal reflux disease (GERD) is a highly preva-
lent gastrointestinal disorder. It is critical that clinical endpoints 
are properly evaluated in order to assess treatment efficacy. 
Clinical tools for assessment of symptoms severity should be dis-
criminative, predictive and evaluative.
1
Any evaluative scale should measure clinical changes (ie, 
symptoms severity) over the time and under treatment (sensitivity 
to detect changes); the scales should be objective and inter-
pretable. Very few clinical tools have been developed and vali-
dated to evaluate the severity of GERD, and so far, there is no 
gold standard to determine the responsiveness of a measurement 
scale in GERD. Despite the subjectivity, GERD questionnaires 
such as Carlsson-Dent are sensitive enough to detect people with 
GERD than endoscopy in a region with low prevalence.
2 The 
subjective assessment of symptoms intensity as related to func-
tional disease indicates that self-assessment is more accurate than 
physician evaluation. This concept is founded on the idea that on-
ly the person who suffers the pain knows its intensity, compared 
to a physician who can make an approximation of the patient’s 
pain. Consequently, some researchers only pay attention to the 
patient’s score of symptoms severity.
3
Clinimetrics is a word derived from biometrics, and it refers 
to measurement of clinical symptoms and procedures which are 
helpful for diagnosis, characterization or evaluation of clinical 
entities. Any clinimetric measurement has its own variance, and 
the source of variation regarding symptoms intensity can be asso-
ciated with factors like race, sex or age. Additionally, other factors 
external to patients can influence the results, such as medical spe-
cialty of the physician administering the interview.
In this study, we tested 2 hypotheses regarding the clini-
metric approach to GERD assessment: (1) symptoms intensity 
score would correlate between physician and patient measure-
ments. To test this, we compared the physician (from several spe-
cialties) measurement using a Likert scale of symptoms intensity 
with sickness impact profile (SIP) vs patients’ measurement with 
ReQuest
TM. We assumed that both scales would have high in-
ternal reliability and a positive coefficient of correlation. We 
measured their sensitivity to detect changes in symptoms severity 
after 4 weeks of pantoprazole magnesium (40 mg orally per day). 
(2) Physician specialty, patients’ disease and characteristics are 
important source of variation in symptoms intensity scores. We 
used a variance decomposition of scores to determine whether the 
amount of information (attributable percentage) of patients and 
physician specialty contributed to the scores. 
Materials and Methods
Study Sample
This was a nation widely conducted study in private, state 
and hospital-based practices in Mexico. We included subjects 
between 18 to 45 years old (we excluded older people to decrease 
the probability of malignancy), with clinical history of heartburn, 
acid regurgitation, or both during the previous 3 months. These 
symptoms were reliable indicators of the presence of GERD, as 
has been found in other questionnaires.
4,5 The present study in-
cluded a wide sample of GERD patients with few clinical re-
strictions, and this design supported external validity of our re-
sults for daily clinical practice.
Questionnaires
We asked physician to conduct a structured interview (SIP) 
driven by questions that explore symptoms severity associated 
with GERD. This SIP has 18 questions divided into classical 
symptoms of GERD (heartburn and regurgitation), dyspepsia 
and extraesophageal manifestations of GERD. The interview 
asked patients to rate severity of heartburn, regurgitation, retch-
ing, halitosis, flatulence, nausea, sialorrhea, globus, discomfort, 
chest pain, dyspnea, chronic cough, early satiety and sleeping 
disturbances. The scale included categories such as “never,” 
“rare,” “sometimes,” “most of the time” and “always.” All of 
them were scored on a Likert scale of 4 points. We had demon-
strated that this structured interview has enough sensitivity to de-
tect group differences for symptoms severity or its changes by 
proton pump inhibitor treatment.
6,7
The patient directed-instrument, ReQuest
TM, is a validated 
questionnaire with high internal consistency (Cronbach α = 
0.90) and test-retest realiability (intraclass correlation coefficient 
between 0.86 for short version and 0.94 for long version).
8 The 
short version has 6 questions with a visual analog scale of 10 cm 
long. The 6 questions vary in scope from general well being 
(quality of life) to acid-related complaints, upper abdominal-re-
lated complaints, lower abdominal-related complaints, nausea 
and sleep disorders.
Statistical Methods
Data were analyzed with SPSS version 15 and Statistica ver-GERD Evaluation After Treatment
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Table 1. Matrix of Correlations between Likert Scores and ReQuest




Quality of life Acid Upper abdominal Lower abdominal Nausea Sleep disorders
Heartburn 0.21 0.24 0.18 0.15 0.10 0.15
Regurgitation 0.21 0.23 0.19 0.17 0.13 0.20
Belching 0.14 0.15 0.15 0.16 0.13 0.14
Sialorrhea 0.08 0.06 0.08 0.19 0.12 0.16
Globus 0.08 0.06 0.07 0.14 0.07 0.13
Dysphagia 0.10 0.08 0.10 0.17 0.11 0.13
Odynophagia 0.11 0.08 0.08 0.15 0.10 0.14
Retching 0.07 0.04 0.09 0.17 0.18 0.14
Halitosis 0.10 0.10 0.13 0.19 0.14 0.17
Gastric pain 0.16 0.13 0.23 0.22 0.15 0.16
Early satiety 0.11 0.09 0.15 0.23 0.17 0.16
Nausea 0.15 0.14 0.18 0.23 0.45 0.20
Flatus 0.08 0.04 0.09 0.26 0.12 0.14
Chest oppression 0.09 0.07 0.14 0.16 0.09 0.13
Dyspnea 0.08 0.04 0.08 0.13 0.07 0.16
Chronic cough 0.05 0.03 0.04 0.12 0.09 0.17
Dysphonia 0.03 0.01 0.04 0.11 0.04 0.13
Sleep disorders 0.19 0.14 0.17 0.22 0.17 0.51
All correlations showed P-value ＜ 0.05.
sion 8.0. The internal reliability was measured with Cronbach al-
pha coefficient,
9 calculated for ReQuest
TM and SIP separately.
Correlation between Likert scores and the ReQuest
TM was 
calculated by Spearman’s test. Dimensionality was assessed by la-
tent factor analysis with a varimax rotation and Kaiser normal-
ization of variables. Those factors with eigenvalue greater than 1 
were considered as non compressed and to be able to represent 
one or more original variables, so they were considered significant 
because they explained an important amount of the variability in 
the data. The extracted scores were used as dependent variables.
Differences between specialties were analyzed using analysis 
of variance (ANOVA) and only those with P ＜ 0.05 were con-
sidered for post hoc test with Fisher method (data expressed as 
mean ± SEM). To understand the source of variance, we per-
formed variance components analysis using type III ANOVA to 
calculate mean squares and the percentage of explained variance. 
The specialty of the physician interviewer was considered as a 
random effect; sex was fixed factor; age and body mass index 
were considered as covariates.
Ethics
All applicable international regulations concerning the ethical 
participation of our volunteers were followed during this resear-
ch. The study and the informed consent document were ap-
proved by the Ethical Committee for Research of the Dr. 
Maximiliano Ruiz Castañeda General Hospital of Naucalpan; 
and the Center of Bioethics of the Medicine Faculty of the 




We invited 1,306 physicians to participate from four branch-
es of medicine (gastroenterology, n = 157; internal medicine, n 
= 218; general surgery, n = 65; and general practitioner, n = 
866). They evaluated 3,665 patients and 2,818 (77%) were in-
cluded in this sample who completed the ReQuest
TM ques-
tionnaire and were suitable for the analysis. We included 1,522 
(54%) women and 1,296 men; their mean age was 36 ± 7 (SD) 
years, and the mean body mass index was 26 ± 4 (SD).
Internal Consistency and Correlation Between 
Sickness Impact Profile and ReQuest
TM
The Cronbach alpha coefficient showed high internal con-
sistency for ReQuest
TM (0.87, P ＜ 0.05) and SIP (0.84, P ＜ 
0.05). Most of the correlation coefficients between ReQuest
TM Juan Carlos Lopez-Alvarenga, et al
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Table 2. Comparison of Sickness Impact Profile and ReQuest












    Age (yr) 35.5 ± 0.3
a 37.2 ± 0.2
b  36.6 ± 0.5
c 35.6 ± 0.1
a,c ＜ 0.001
    Sex (M/F)    172/223    285/339      61/72    961/1,087 0.653
    BMI 25.5 ± 0.2
c 26.2 ± 0.1
b 25.6 ± 0.4
b,c 26.4 ± 0.1
b 0.002
Likert score (SIP)
    Heartburn 2.38 ± 0.03
b 2.21 ± 0.02
c 2.00 ± 0.06
a 2.24 ± 0.01
c ＜ 0.001
    Regurgitation 2.14 ± 0.04
b 2.13 ± 0.03
b 1.94 ± 0.06
c 2.16 ± 0.01
b  0.024
    Belching 1.49 ± 0.05 1.53 ± 0.03 1.35 ± 0.08 1.56 ± 0.02  0.062
    Sialorrhea 0.66 ± 0.04 0.67 ± 0.03 0.60 ± 0.08 0.71 ± 0.02  0.358
    Globus 0.74 ± 0.04
a 0.76 ± 0.03
a 1.10 ± 0.09
b 0.87 ± 0.02
c ＜ 0.001
    Dysphagia 0.50 ± 0.04
a 0.56 ± 0.03
a 0.90 ± 0.08
b 0.74 ± 0.02
c ＜ 0.001
    Odynophagia 0.36 ± 0.03
a 0.47 ± 0.03
c 0.89 ± 0.08
b 0.53 ± 0.01
c ＜ 0.001
    Retching 0.43 ± 0.03 0.48 ± 0.03 0.52 ± 0.07 0.52 ± 0.01  0.235
    Halitosis 0.84 ± 0.05
c 0.89 ± 0.04
c 0.90 ± 0.08
b,c 1.00 ± 0.02
b  0.005
    Gastric pain 1.78 ± 0.05
c 1.81 ± 0.03
c 1.45 ± 0.09
a 1.89 ± 0.02
b ＜ 0.001
    Early satiety 1.08 ± 0.05
b,c 1.03 ± 0.04
b,c 0.93 ± 0.08
c 1.12 ± 0.02
b  0.062
    Nausea 1.06 ± 0.05
b 1.04 ± 0.03
b 0.82 ± 0.08
c 1.04 ± 0.02
b  0.090
    Flatus 0.95 ± 0.05
c 0.95 ± 0.04
c 0.93 ± 0.08
c 1.12 ± 0.02
b ＜ 0.001
    Chest oppression 1.05 ±0.05
b,c 1.13 ± 0.04
b 0.88 ± 0.08
c 1.16 ± 0.02
b  0.016
    Dyspnea 0.30 ± 0.03 0.37 ± 0.03 0.29 ± 0.05 0.34 ± 0.01  0.426
    Chronic cough 0.41 ± 0.04
b 0.49 ± 0.03
b 0.77 ± 0.08
c 0.45 ± 0.01
b ＜ 0.001
    Dysphonia 0.45 ± 0.04
c 0.54 ± 0.03
c 0.77 ± 0.08
b 0.48 ± 0.01
c ＜ 0.001
    Sleep disorders 1.00 ± 0.05
c 1.06 ± 0.04
c 1.03 ± 0.09




    Quality of life 6.12 ± 0.14 6.17 ± 0.11 5.85 ± 0.23 6.33 ± 0.06 0.127
    Acid complaints 6.24 ± 0.15 6.25 ± 0.12 5.71 ± 0.25 6.39 ± 0.06 0.068
    Upper abdominal or stomach somplaints 5.82 ± 0.15
b 5.97 ± 0.12
b 5.18 ± 0.26
c 6.10 ± 0.06
b 0.003
    Lower abdominal or digestive complaints 4.42 ± 0.16
c 4.57 ± 0.13
b,c 4.40 ± 0.26
b,c 4.82 ± 0.06
b 0.036
    Nausea 3.80 ± 0.16
b,c 4.01 ± 0.13
b,c 3.22 ± 0.25
c 4.04 ± 0.07
b 0.025
    Sleep disorders 4.09 ± 0.17
c 4.23 ± 0.13
b,c 3.84 ± 0.29
c 4.48 ± 0.07
b 0.033
a,b,cIndicate homogeneous groups using Scheffe contrast, where b ＞ c ＞ a.
BMI, body mass index; SIP, sickness impact profile.
Data were expressed as mean ± SEM.
and SIP were small (between 0.03 and 0.26); only nausea (r = 
0.45, P ＜ 0.001) and sleep disorders (r = 0.51, P ＜ 0.001) 
were highly correlated. Table 1 shows this matrix correlation.
Dimensionality of Scales
The factor analysis including both measurements showed 5 
main factors, and one of these factors (F1) was the ReQuest
TM 
itself. The other four factors can be described as F2: dyspepsia; 
F3: sleep disorders and cough; F4: symptoms associated with 
larynx-upper esophagus region such as hoarseness, odynophagia, 
dysphagia and globus; and F5: classical GERD symptom (heart-
burn and regurgitation). The obtained factors, calculated by 
principal component analysis, were orthogonal to each other; 
which meant by definition that they did not have correlation be-
tween calculated scores. 
Variance Decomposition of the Scores
The ANOVA found differences in symptoms intensity and 
ReQuest
TM scores by physician specialty (Table 2). Gastroenter-
ologists gave the highest scores for heartburn and regurgitation; 
surgeons gave the highest scores for symptoms associated with 
upper respiratory or esophageal symptoms like odynophagia, dys-
phagia and globus. General practictioners gave the highest scores 
for other symptoms like flatus and dyspepsia (Table 2). The sex 
adjustment showed that women had higher scores for symptoms 
severity than men (data not shown) as has been found in other GERD Evaluation After Treatment
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Figure. Symptoms improvement after 4 weeks of treatment with pinverium bromide plus symeticon. (A) It Shows patient evaluation with ReQuest
TM.
(B) It shows physician evaluation with a structured interview, despite the lack of correlation both measurements improved significantly with treatment.
Both assessment showed significant amelioration of symptoms (P ＜ 0.05 for all variables).
studies.
The variance decomposition showed the effect of specialty in 
less than 2% compared to the total variance. Interestingly, despite 
the lack of correlation between both evaluations, SIP and 
ReQuest
TM, showed a clinically and statistically significant re-
sponse after the 4 weeks pantoprazole treatment (Figure).
Discussion
This study demonstrated that symptoms severity of GERD 
assessed by physicians did not correlate with symptoms severity 
assessed by patients. This could be interpreted as assessment of 
different aspects (2 different points of view of the same patients’ 
symptoms). Interestingly, the physician-administered and pa-
tient-administered tools have high internal reliability for meas-
urement of the same disease, but they were non-correlated as we 
demonstrated orthogonality in a multiple dimensional-mathema-
tical space (latent factor analysis). In other words, they measure 
diverse dimensions, and one of them is occupied by all ReQuest
TM 
questions, while the other four factors were measured by the 
physician evaluation with SIP. However, both tools recorded im-
provement of patients’ symptoms after 4 weeks of pantoprazole 
magnesium treatment, which meant that GERD measured in 
multidimensional traits improved with treatment.
 
Clinimetry Should Be Evaluated by Physicians 
or Patients?
We expected a positive correlation between the questions of 
the structured interview and ReQuest
TM, but instead we found 
that evaluation of SIP and ReQuest
TM was orthogonal. Thus, 
even though both physicians and patients were evaluating the 
same disease, the dimensions measured were not the same. After 
treatment, measurements by both tools showed improvement.
Neither of the measurements showed any great advantage 
over the other in evaluating symptoms severity during treatment. 
Moreover, the multidimensionality of the evaluation helped to 
check improvement not only for classical GERD symptoms 
(heartburn and regurgitation) but also for extraesophageal and 
overlapping symptoms. Some of the score variations in both tools 
were due to: perception associated with the medical specialty of 
the physician and women’s perception of symptoms severity. We 
think that in a larger sample size, the effect of the medical spe-
cialty of the participating physicians would diminish the total er-
ror variation. For a smaller sample size, the stratification of spe-
cialties becomes the rule. Perhaps then the next questions should 
be, when to evaluate the symptoms, and who should initiate the 
evaluation: physician or patients?
Advantages of the Method
The methods we used had some interesting components. We Juan Carlos Lopez-Alvarenga, et al
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invited a large number of centers to participate in the study in or-
der to increase external validity of our results for daily clinical 
practice.
It has been recommended that patient-driven evaluation of 
symptoms is the most effective. The logic of this suggestion is 
based on the subjectivity of evaluation about severity on any func-
tional disease. Patients know better than physicians how they 
feel.
10 We compared 2 tools that should be antagonic from this 
point of view, a tool filled by patients and another tool filled by 
physician. The high alpha coefficient support that the structured 
questions and the ReQuest
TM have a coherent structure, the lack 
of correlation with the orthogonal dimension corroborated by fac-
tor analysis, which is consistent witht ReQuest
TM being an unidi-
mensional measurement, while the structured interview covers 4 
dimensions. We analyzed the variance composition of the latent 
factor scores and found the medical specialty of the physician in-
fluenced the perception of symptoms severity of GERD.
Limitations of the Study
The relationship between ReQuest
TM and the structured in-
terview remains unclear; despite the fact that they were un-
correlated, both tools measured improvement with treatment, 
meaning that they had a communality affected by treatment. We 
will study further the co-decomposition of variance between these 
tools.
The factor analysis should be use to rebuild the structured 
interview. The factor scores obtained are non-dimensional, how-
ever, they can be helpful to select a new clusters of questions to 
evaluate symptoms intensity for GERD.
Conclusions
We conclude that the patient- and physician-driven tools do 
not correlate because they measure diverse orthogonal dimen-
sions. However, both tools are sensitive enough to detect favor-
able changes in symptoms severity associated with treatment with 
pantoprazol magnesium after 4 weeks.
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